Phase I Dose Escalation Trial of MEK1/2 Inhibitor MSC1936369B Combined With Temsirolimus in Subjects With Advanced Solid Tumors.

Trial Profile

Phase I Dose Escalation Trial of MEK1/2 Inhibitor MSC1936369B Combined With Temsirolimus in Subjects With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Pimasertib (Primary) ; Temsirolimus
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Feb 2017 Results assessing maximum tolerated dose, recommended phase 2 dose of pimasertib in combination with temsirolimus as well as safety and pharmacokinetics published in the Investigational New Drugs.
    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top